Pantaleo G, De Maria A, Koenig S, Butini L, Moss B, Baseler M, Lane H C, Fauci A S
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Proc Natl Acad Sci U S A. 1990 Jun;87(12):4818-22. doi: 10.1073/pnas.87.12.4818.
In this study, we have investigated the potential mechanisms responsible for the loss of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic activity in the advanced stages of HIV-1 infection. We have demonstrated that HIV-1-specific cytotoxic T lymphocytes are predominantly contained within the CD8+DR+ subset. Furthermore, we have shown by a redirected killing assay that there is a dichotomy between HIV-1-specific cytolytic activity and broad cytolytic potential since the cytolytic machinery of CD8+DR+ cells is still functioning even in patients with AIDS who have lost their HIV-1-specific cytolytic activity. In addition, by comparative analysis of these two types of cytolytic activity over time we have demonstrated a progressive loss of HIV-1-specific cytolytic activity in the advanced stages of the disease, whereas the cytolytic potential remained unchanged regardless of the clinical stage. As previously shown in patients with AIDS, even in asymptomatic HIV-1-seropositive patients, CD8+DR+ cells from the same patient, compared to CD8+DR- lymphocytes, showed a substantial reduction in their ability to proliferate in vitro in response to different stimuli, such as mitogens (phytohemagglutinin and phorbol 12-myristate 13-acetate) and monoclonal antibodies directed against CD3, CD2, and CD28 molecules, and displayed a defective clonogenic potential. Thus, on the basis of these results we propose that the loss of HIV-1-specific cytolytic activity in HIV-1-infected individuals may result at least in part from a progressive decrease in the pool of HIV-1-specific cytotoxic T lymphocytes belonging to the CD8+DR+ subset whose ability to expand has been impaired.
在本研究中,我们调查了在人类免疫缺陷病毒1型(HIV-1)感染晚期导致HIV-1特异性细胞溶解活性丧失的潜在机制。我们已经证明,HIV-1特异性细胞毒性T淋巴细胞主要存在于CD8+DR+亚群中。此外,我们通过重定向杀伤试验表明,HIV-1特异性细胞溶解活性与广泛的细胞溶解潜能之间存在二分法,因为即使在已丧失HIV-1特异性细胞溶解活性的艾滋病患者中,CD8+DR+细胞的细胞溶解机制仍在发挥作用。此外,通过对这两种细胞溶解活性随时间的比较分析,我们证明了在疾病晚期HIV-1特异性细胞溶解活性逐渐丧失,而细胞溶解潜能无论临床阶段如何均保持不变。如先前在艾滋病患者中所显示的,即使在无症状的HIV-1血清阳性患者中,与CD8+DR-淋巴细胞相比,同一患者的CD8+DR+细胞在体外对不同刺激(如丝裂原(植物血凝素和佛波醇12-肉豆蔻酸酯13-乙酸酯)以及针对CD3、CD2和CD28分子的单克隆抗体)的增殖能力也显著降低,并且显示出克隆形成潜能存在缺陷。因此,基于这些结果我们提出,HIV-1感染个体中HIV-1特异性细胞溶解活性的丧失可能至少部分是由于属于CD8+DR+亚群的HIV-1特异性细胞毒性T淋巴细胞池逐渐减少,其扩增能力受到损害。